Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Treatment Options in Oncology
Published in: Current Treatment Options in Oncology 1-2/2010

01-06-2010 | Gastrointestinal Malignancies

Circulating Tumor Cells in Colorectal Cancer: Past, Present, and Future Challenges

Authors: Benjamin P. Negin, MD, Steven J. Cohen, MD

Published in: Current Treatment Options in Oncology | Issue 1-2/2010

Login to get access

Opinion statement

Recent advances in immunomagnetic separation and flow cytometry have made the detection and characterization of circulating tumor cells (CTC) a reality. This technology has already demonstrated prognostic significance in breast and prostate cancer. In the current review, we will review the historical and current data regarding the enumeration and identification of CTC in colorectal cancer. With immunomagnetic separation techniques, CTC can reliably and reproducibly be identified within 1 to 2 cells in a 7.5 mL sample of peripheral blood. Prospective studies have demonstrated a significant adverse impact on survival with the presence of ≥3 CTC per 7.5 mL blood. Approximately one quarter of patients with metastatic disease will be categorized in this poor prognosis group. In addition, change in number of cells on treatment has prognostic significance. While CTC enumerated through immunomagnetic separation are a clear prognostic factor for patients with mCRC, the future challenge is to study whether treatment decision-making should be impacted by their level. Low cell yield in mCRC is a potential hinderance to answering these important clinical questions at present. CTC can also be isolated and studied with flow cytometry, FISH, and RT-PCR, allowing real-time assessment of tumor biology. Future advances in this field will improve both the detection and manipulation of these cells. Improvements in detection and characterization of CTC will hopefully lead to refinement of the surgical and chemotherapeutic treatment of colorectal cancer.
Literature
1.
2.
Hochster HS, et al.: Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 2008, 26(21):3523–3529.CrossRefPubMed
3.
Sanoff HK, et al.: Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol 2008, 26(35):5721–5727.CrossRefPubMed
4.
Tournigand C, et al.: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004, 22(2):229–237.CrossRefPubMed
5.
Van Cutsem E, et al.: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009, 360(14):1408–1417.CrossRefPubMed
6.
Amado RG, et al.: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26(10):1626–1634.CrossRefPubMed
7.
Van Cutsem E, et al.: KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience. J Clin Oncol, 2008, 26(May 20 suppl; abstr 2)
8.
Falcone A, et al.: FOLFOXIRI (irinotecan, oxaliplatin, and infusional 5FU/LV) in combination with bevacizumab (BV) in the first-line treatment of metastatic colorectal cancer (mCRC): a phase II study by the G.O.N.O. group. J Clin Oncol, 2008, 26(May 20 suppl; abstr 4031)
9.
10.
Pelkey TJ, Frierson HF Jr, Bruns DE: Molecular and immunological detection of circulating tumor cells and micrometastases from solid tumors. Clin Chem 1996, 42(9):1369–1381.PubMed
11.•
Racila E, et al.: Detection and characterization of carcinoma cells in the blood. Proc Natl Acad Sci USA 1998, 95(8):4589–4594.CrossRefPubMed
12.
Koelink PJ, et al.: Circulating cell death products predict clinical outcome of colorectal cancer patients. BMC Cancer 2009, 9:88.CrossRefPubMed
13.
Allen-Mersh TG, et al.: Role of circulating tumour cells in predicting recurrence after excision of primary colorectal carcinoma. Br J Surg 2007, 94(1):96–105.CrossRefPubMed
14.
Gala JL, et al.: Expression of prostate-specific antigen and prostate-specific membrane antigen transcripts in blood cells: implications for the detection of hematogenous prostate cells and standardization. Clin Chem 1998, 44(3):472–481.PubMed
15.
Smith MR, Biggar S, Hussain M: Prostate-specific antigen messenger RNA is expressed in non-prostate cells: implications for detection of micrometastases. Cancer Res 1995, 55(12):2640–2644.PubMed
16.
Lopez-Guerrero JA, et al.: Minimal illegitimate levels of cytokeratin K19 expression in mononucleated blood cells detected by a reverse transcription PCR method (RT-PCR). Clin Chim Acta 1997, 263(1):105–116.CrossRefPubMed
17.
Molnar B, et al.: Molecular detection of circulating cancer cells. Role in diagnosis, prognosis and follow-up of colon cancer patients. Dig Dis 2003, 21(4):320–325.CrossRefPubMed
18.•
Molnar B, et al.: Circulating tumor cell clusters in the peripheral blood of colorectal cancer patients. Clin Cancer Res 2001, 7(12):4080–4085.PubMed
19.
Witzig TE, et al.: Detection of circulating cytokeratin-positive cells in the blood of breast cancer patients using immunomagnetic enrichment and digital microscopy. Clin Cancer Res 2002, 8(5):1085–1091.PubMed
20.•
Allard WJ, et al.: Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004, 10(20):6897–6904.CrossRefPubMed
21.
Cohen SJ, et al.: Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer. Clin Colorectal Cancer 2006, 6(2):125–132.CrossRefPubMed
22.••
Cohen SJ, et al.: Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26(19):3213–3221.CrossRefPubMed
23.
Groot M, et al.: Circulating tumor cells (CTC) in newly diagnosed breast or colorectal cancers. J Clin Oncol 2007, 25(18S: June 20 Suppl: abstr 14512)
24.•
Hiraiwa K, et al.: Clinical significance of circulating tumor cells in blood from patients with gastrointestinal cancers. Ann Surg Oncol 2008, 15(11):3092–3100.CrossRefPubMed
25.•
Sastre J, et al.: Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables. Ann Oncol 2008, 19(5):935–938.CrossRefPubMed
26.••
Cristofanilli M, et al.: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004, 351(8):781–791.CrossRefPubMed
27.
Moreno JG, et al.: Changes in circulating carcinoma cells in patients with metastatic prostate cancer correlate with disease status. Urology 2001, 58(3):386–392.CrossRefPubMed
28.
Krivacic RT, et al.: A rare-cell detector for cancer. Proc Natl Acad Sci USA 2004, 101(29):10501–10504.CrossRefPubMed
29.
Nagrath S, et al.: Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007, 450(7173):1235–1239.CrossRefPubMed
30.
Maheswaran S, et al.: Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008, 359(4):366–377.CrossRefPubMed
31.••
Cohen SJ, et al.: Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol 2009, 20(7):1223–1229.
32.
Tol J, et al.: Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009, 360(6):563–572.CrossRefPubMed
33.••
Koopman M, et al.: Circulating tumor cells (CTC) in advanced colorectal cancer (ACC) patients undergoing 1st line treatment with chemotherapy, bevacizumab and cetuximab as an important and early predictor of survival. Ann Oncol 2008, 19(suppl 8: viii 166)
34.
Wong SC, et al.: Clinical significance of cytokeratin 20-positive circulating tumor cells detected by a refined immunomagnetic enrichment assay in colorectal cancer patients. Clin Cancer Res 2009, 15(3):1005–1012.CrossRefPubMed
35.
Matsusaka S, et al.: Use of circulating tumor cells and circulating endothelial cells as surrogate markers for FOLFOX4 with or without bevacizumab in mCRC. ASCO Gastrointestinal Cancers Symp, 2009 (abstr 345)
36.
Hurwitz H, et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350(23):2335–2342.CrossRefPubMed
37.
Falcone A, et al.: Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007, 25(13):1670–1676.CrossRefPubMed
38.
Fong Y, et al.: Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999, 230(3):309–318; discussion 318–321.CrossRefPubMed
39.
40.
Nordlinger B, et al.: Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008, 371(9617):1007–1016.CrossRefPubMed
41.
Andre T, et al.: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004, 350(23):2343–2351.CrossRefPubMed
42.
Wolmark N, et al.: A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: results of NSABP Protocol C-08. J Clin Oncol 2009, 27(18 suppl; abstr LBA4)
43.
Kerr D, et al.: A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study. J Clin Oncol 2009, 27(15 suppl; abstr 4000)
44.
de Bono JS, et al.: Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clin Cancer Res 2007, 13(12):3611–3616.CrossRefPubMed
45.
Guo J, et al.: Detection of cytokeratin 20 mRNA in the peripheral blood of patients with colorectal cancer by immunomagnetic bead enrichment and real-time reverse transcriptase-polymerase chain reaction. J Gastroenterol Hepatol 2005, 20(8):1279–1284.CrossRefPubMed
46.
Lim HJ, et al.: EGFR staining of circulating tumor cells (CTCs) from patients with metastatic colorectal cancer. ASCO Gastrointestinal Cancers Symp 2009 (abstr 373)
47.
Van Cutsem E, et al.: Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007, 25(13):1658–1664.CrossRefPubMed
48.
Hendlisz A, et al.: Modulation and prognostic value of epidermal growth factor receptor (EGFR) expression in circulating tumor cells (CTCs) during chemotherapy (CT) in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26(May 20 suppl; abstr 15038)
Metadata
Title
Circulating Tumor Cells in Colorectal Cancer: Past, Present, and Future Challenges
Authors
Benjamin P. Negin, MD
Steven J. Cohen, MD
Publication date
01-06-2010
Publisher
Springer US
Published in
Current Treatment Options in Oncology / Issue 1-2/2010
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI
https://doi.org/10.1007/s11864-010-0115-3

Other articles of this Issue 1-2/2010

Current Treatment Options in Oncology 1-2/2010 Go to the issue

Gastrointestinal Malignancies

Treatment Options for Surgically Resectable Gastric Cancer

Lung Cancer

Alternatives to Surgery for Early Stage Non-Small Cell Lung Cancer-Ready for Prime Time?

Lung Cancer

Exciting New Targets in Lung Cancer Therapy: ALK, IGF-1R, HDAC, and Hh

Alternative Therapies

Exercise Therapy in the Management of Solid Tumors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits